RHHBY - iTeos Therapeutics shares rise 4% as Wedbush ups price target

Wedbush analyst David Nierengarten is maintaining his overweight rating on shares of iTeos Therapeutics (ITOS) and increasing his price target to $52 from $46.Nierengarten is bullish on upcoming phase 1/2 results on EOS-448 for immune-resistant advanced cancers that will be presented next month at the American Association for Cancer Research.He says that EOS-448 is most comparable to Roche's (RHHBY) Genentech subsidiary tiragolumab, but with better anti-TIGIT activity in preclinical studies. TIGIT is a key inhibitor of anti-tumor responses.The company reported Q4 2020 EPS yesterday that just missed analysts' expectations.iTeos closed up 4% today to $32.09.

For further details see:

iTeos Therapeutics shares rise 4% as Wedbush ups price target